NOT FOR
RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY
OR INDIRECTLY IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO
WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF
SUCH JURISDICTION.
This
announcement does not constitute or form part of an offer to sell
or issue or a solicitation of an offer to subscribe for or buy any
securities nor should it be relied upon in connection with any
contract or commitment whatsoever in any jurisdiction. Investors
should not subscribe for or purchase any securities referred to in
this announcement except solely on the basis of the information
contained in the admission document, including the risk factors set
out therein, published by Optima Health plc (the "Company" or
"Optima") on 23 September 2024 in connection with the admission of
the ordinary shares in the capital of the Company to trading on
AIM, a market operated by London Stock Exchange plc (the "Admission
Document").
Optima Health plc
("Optima", the
"Company", and, together with its subsidiaries, the
"Group")
First Day of Dealings on AIM
- UK's largest provider of
corporate health and wellbeing solutions
- Cash generative and
profitable (on adjusted basis)
- FY2024 revenues of 110.9
million and adjusted EBITDA of £18.0 million
LONDON,
UK., 26 September 2024, Optima Health, the UK's
leading provider of technology enabled corporate health and
wellbeing solutions, is pleased to announce the admission of its
Ordinary Shares to trading on AIM, a market operated by London
Stock Exchange plc ("Admission").
Dealings in the Company's ordinary
shares of £0.01 each in the capital of the Company ("Ordinary
Shares") will commence at 8.00 a.m. today under the ticker "OPT"
(ISIN: GB00BRSCY602). On Admission, the Company will
have 88,776,226 Ordinary Shares in issue and no Ordinary Shares
held in treasury.
Jonathan Thomas,
Chief Executive Officer of Optima Health, commented:
"We are delighted to begin Optima
Health's journey as an AIM-listed company. As an independent
business, we are
well positioned to continue our successful track record of growth,
both organic and through successful acquisition and integration,
within the strong and growing occupational health market in the UK.
Being a publicly listed company will provide us with an opportunity
to build and deliver significant value for our shareholders and
employees and we look forward to beginning this exciting new
chapter in our story."
Admission
The Directors believe that Admission will be an
important step in the Group's development and will assist the Group
in its development by raising its public profile, widening its
shareholder base, providing potential future access to development
capital to progress its current and future pipeline of proprietary
products and enabling it to expand within its core areas and expand
its commercial partnerships. It will also provide the Group with
the ability to incentivise its employees through share incentive
plans, which should assist it in continuing to attract, retain and
motivate high calibre employees.
No new capital was raised through an offer or sale of
Ordinary Shares to institutional investors or the public in
connection with Admission. Prior to Admission, the Optima Health
executive management team subscribed for new Ordinary Shares in the
Company, in connection with the settlement of the Company's legacy
senior management share incentive plan, as further described in the
Admission Document.
Unless otherwise indicated, capitalised terms in this
Announcement have the meaning given to them in the Admission
Document.
Enquiries
Optima Health
Jonathan Thomas, CEO
Heidi Giles, CFO
|
+44(0)3300085113
media@OptimaHealth.co.uk
|
Nominated Adviser and Corporate Broker
Panmure Liberum Limited
Emma Earl / Will Goode/ Mark
Rogers
Rupert Dearden
|
+44 (0)20 3100 2000
|
UK
Financial PR Adviser
ICR Consilium
Mary-Jane Elliott / Angela Gray /
Chris Welsh
|
optimahealth@icrinc.com
|
|
|
About Optima
Health
Optima Health is the UK's leading provider of
occupational health and wellbeing services, directly influencing
and improving people's lives for 25 years. Optima Health's
incredible team of professionals quickly and effectively
encapsulate client's needs, supporting organisations of all shapes
and sizes. Through tailored solutions and innovative systems,
Optima Health offers unparalleled clinical expertise to its
clients. These solutions ensure that processes are simple and allow
its clients to spend more time focusing on their employees driving
a healthy, high-performing workplace. For more information
visit www.optimahealth.co.uk.
IMPORTANT NOTICES
This announcement does not constitute, or form
part of, any offer or invitation to sell, allot or issue, or any
solicitation of any offer to purchase or subscribe for, any
securities in the Company in any jurisdiction nor shall it, or any
part of it, or the fact of its distribution, form the basis of, or
be relied on in connection with or act as an inducement to enter
into, any contract or commitment therefor.
No reliance may be placed, for any purpose
whatsoever, on the information or opinions contained in this
announcement or on its accuracy, fairness or completeness. To the
fullest extent permitted by applicable law or regulation, no
undertaking, representation or warranty, express or implied, is
given by or on behalf of the Company, Panmure Liberum Limited
("Panmure Liberum"), or
their respective parent or subsidiary undertakings or the
subsidiary undertakings of any such parent undertakings or any of
their respective directors, officers, partners, employees, agents,
affiliates, representatives or advisers or any other person as to
the accuracy, sufficiency, completeness or fairness of the
information, opinions or beliefs contained in this announcement and
no responsibility or liability is accepted by any of them for any
errors, omissions or inaccuracies in such information, opinions or
beliefs or for any loss, cost or damage suffered or incurred,
howsoever arising, from any use, as a result of the reliance on, or
otherwise in connection with, this announcement.
Panmure Liberum, which is authorised and
regulated by the Financial Conduct Authority is acting only for the
Company in connection with Admission and is not acting for or
advising any other person, or treating any other person as its
client, in relation thereto, or giving advice to any other person
in relation to the matters contained herein. Such persons should
seek their own independent legal, investment and tax advice as they
see fit. Panmure Liberum's responsibilities, as the Company's
nominated adviser under the AIM Rules for Nominated Advisers and
AIM Rules for Companies will be owed solely to the London Stock
Exchange and not to the Company, to any of its directors or to any
other person in respect of a decision to subscribe for or otherwise
acquire Shares in reliance on the Admission Document. No
representation or warranty, express or implied, is made by Panmure
Liberum or the Company or their respective affiliates, directors,
officers, employees or advisers as to any of its
contents.
This announcement does not form the basis of or
constitute any offer or invitation to sell or issue, or any
solicitation of any offer to purchase or subscribe for any Shares
or any other securities nor shall it (or any part of it) or the
fact of its distribution, form the basis of, or be relied on in
connection with, any contract or commitment therefor. No offer or
sale of the Shares has been and will not be registered under the
applicable securities laws of the United States, Australia, Canada,
Japan or South Africa. Subject to certain exceptions, the Shares
may not be offered or sold in the United States, Australia, Canada,
Japan or South Africa or to, or for the account or benefit of, any
national, resident or citizen of the United States, Australia,
Canada, Japan or South Africa. There will be no public offer of the
Shares in the United States, Australia, Canada, Japan or South
Africa.
This announcement may include statements that
are, or may be deemed to be, "forward-looking statements". These
forward-looking statements may be identified by the use of
forward-looking terminology, including the terms "believes",
"estimates", "plans", "projects", "anticipates", "expects",
"intends", "may", "will" or "should" or, in each case, their
negative or other variations or comparable terminology, or by
discussions of strategy, plans, objectives, goals, future events or
intentions. These statements reflect beliefs of the Directors
(including based on their expectations arising from pursuit of the
Company's strategy) as well as assumptions made by the Directors
and information currently available to the Company. Although the
Directors consider that these beliefs and assumptions are
reasonable, by their nature, forward-looking statements involve
known and unknown risks, uncertainties, assumptions and other
factors that may cause the Company's actual financial condition,
results of operations, cash flows, liquidity or prospects to be
materially different from any future such metric expressed or
implied by such statements. Past performance cannot be relied upon
as a guide to future performance and should not be taken as a
representation that trends or activities underlying past
performance will continue in the future. Forward-looking statements
speak only as of the date they are made. No representation is made
or will be made that any forward-looking statements will come to
pass or prove to be correct.
Whilst the contents of this announcement are
believed to be true and accurate as at the date of its publication,
no representation or warranty is made as to such contents
continuing to be true and accurate at any point in the
future.
For the avoidance of doubt, the contents of the
Company's websites and social media accounts are not incorporated
by reference into, and do not form part of, this
announcement.